Search

Your search keyword '"Andriole, Gerald L"' showing total 1,572 results
Start Over Author "Andriole, Gerald L"
1,572 results on '"Andriole, Gerald L"'

3. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

Author

Wang, Anqi, Shen, Jiayi, Rodriguez, Alex A., Saunders, Edward J., Chen, Fei, Janivara, Rohini, Darst, Burcu F., Sheng, Xin, Xu, Yili, Chou, Alisha J., Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Plym, Anna, Sahimi, Ali, Hoffman, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Laisk, Triin, Figuerêdo, Jéssica, Muir, Kenneth, Ito, Shuji, Liu, Xiaoxi, Uchio, Yuji, Kubo, Michiaki, Kamatani, Yoichiro, Lophatananon, Artitaya, Wan, Peggy, Andrews, Caroline, Lori, Adriana, Choudhury, Parichoy P., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokolorczyk, Dominika, Lubinski, Jan, Rentsch, Christopher T., Cho, Kelly, Mcmahon, Benjamin H., Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Borge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Andreas, Stroomberg, Hein V., Batra, Jyotsna, Chambers, Suzanne, Horvath, Lisa, Clements, Judith A., Tilly, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordstrom, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie, Cook, Michael B., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Koutros, Stella, Beane Freeman, Laura E., Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Geraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Butler, Ebonee N., Mohler, James L., Taylor, Jack A., Kogevinas, Manolis, Dierssen-Sotos, Trinidad, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Pilie, Patrick, Yu, Yao, Bohlender, Ryan J., Gu, Jian, Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Brenner, Hermann, Chen, Xuechen, Holleczek, Bernd, Schöttker, Ben, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine M., Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Abraham, Aswin, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer, Petrovics, Gyorgy, Casey, Graham, Wang, Ying, Tettey, Yao, Lachance, Joseph, Tang, Wei, Biritwum, Richard B., Adjei, Andrew A., Tay, Evelyn, Truelove, Ann, Niwa, Shelley, Yamoah, Kosj, Govindasami, Koveela, Chokkalingam, Anand P., Keaton, Jacob M., Hellwege, Jacklyn N., Clark, Peter E., Jalloh, Mohamed, Gueye, Serigne M., Niang, Lamine, Ogunbiyi, Olufemi, Shittu, Olayiwola, Amodu, Olukemi, Adebiyi, Akindele O., Aisuodionoe-Shadrach, Oseremen I., Ajibola, Hafees O., Jamda, Mustapha A., Oluwole, Olabode P., Nwegbu, Maxwell, Adusei, Ben, Mante, Sunny, Darkwa-Abrahams, Afua, Diop, Halimatou, Gundell, Susan M., Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Kachuri, Linda, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Preuss, Michael H., Loos, Ruth J. F., Zawistowski, Matthew, Zöllner, Sebastian, Lu, Zeyun, Van Den Eeden, Stephen K., Easton, Douglas F., Ambs, Stefan, Edwards, Todd L., Mägi, Reedik, Rebbeck, Timothy R., Fritsche, Lars, Chanock, Stephen J., Berndt, Sonja I., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Gaziano, J. Michael, Justice, Amy C., Mancuso, Nick, Terao, Chikashi, Eeles, Rosalind A., Kote-Jarai, Zsofia, Madduri, Ravi K., Conti, David V., and Haiman, Christopher A.

Published
2023
Full Text
View/download PDF

4. Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium

Author

Chang, Peter, Wagner, Andrew A, Regan, Meredith M, Smith, Joseph A, Saigal, Christopher S, Litwin, Mark S, Hu, Jim C, Cooperberg, Matthew R, Carroll, Peter R, Klein, Eric A, Kibel, Adam S, Andriole, Gerald L, Han, Misop, Partin, Alan W, Wood, David P, Crociani, Catrina M, Greenfield, Thomas K, Patil, Dattatraya, Hembroff, Larry A, Davis, Kyle, Stork, Linda, Spratt, Daniel E, Wei, John T, Sanda, Martin G, and Consortium, and the PROST-QA RP2

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Pain Research, Chronic Pain, Urologic Diseases, Cancer, 6.4 Surgery, Evaluation of treatments and therapeutic interventions, Aged, Humans, Laparoscopy, Male, Middle Aged, Prospective Studies, Prostatectomy, Prostatic Neoplasms, Quality of Life, Robotic Surgical Procedures, Treatment Outcome, prostatectomy, robotic surgical procedures, quality of life, PROST-QA/RP2 Consortium
Abstract

PurposeOur goal was to evaluate the comparative effectiveness of robot-assisted laparoscopic prostatectomy (RALP) and open radical prostatectomy (ORP) in a multicenter study.Materials and methodsWe evaluated men with localized prostate cancer at 11 high-volume academic medical centers in the United States from the PROST-QA (2003-2006) and the PROST-QA/RP2 cohorts (2010-2013) with a pre-specified goal of comparing RALP (549) and ORP (545). We measured longitudinal patient-reported health-related quality of life (HRQOL) at pre-treatment and at 2, 6, 12, and 24 months, and pathological and perioperative outcomes/complications.ResultsDemographics, cancer characteristics, and margin status were similar between surgical approaches. ORP subjects were more likely to undergo lymphadenectomy (89% vs 47%; p

Published
2022

5. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Author

Giri, Veda N, Knudsen, Karen E, Kelly, William K, Cheng, Heather H, Cooney, Kathleen A, Cookson, Michael S, Dahut, William, Weissman, Scott, Soule, Howard R, Petrylak, Daniel P, Dicker, Adam P, AlDubayan, Saud H, Toland, Amanda E, Pritchard, Colin C, Pettaway, Curtis A, Daly, Mary B, Mohler, James L, Parsons, J Kellogg, Carroll, Peter R, Pilarski, Robert, Blanco, Amie, Woodson, Ashley, Rahm, Alanna, Taplin, Mary-Ellen, Polascik, Thomas J, Helfand, Brian T, Hyatt, Colette, Morgans, Alicia K, Feng, Felix, Mullane, Michael, Powers, Jacqueline, Concepcion, Raoul, Lin, Daniel W, Wender, Richard, Mark, James Ryan, Costello, Anthony, Burnett, Arthur L, Sartor, Oliver, Isaacs, William B, Xu, Jianfeng, Weitzel, Jeffrey, Andriole, Gerald L, Beltran, Himisha, Briganti, Alberto, Byrne, Lindsey, Calvaresi, Anne, Chandrasekar, Thenappan, Chen, David YT, Den, Robert B, Dobi, Albert, Crawford, E David, Eastham, James, Eggener, Scott, Freedman, Matthew L, Garnick, Marc, Gomella, Patrick T, Handley, Nathan, Hurwitz, Mark D, Izes, Joseph, Karnes, R Jeffrey, Lallas, Costas, Languino, Lucia, Loeb, Stacy, Lopez, Ana Maria, Loughlin, Kevin R, Lu-Yao, Grace, Malkowicz, S Bruce, Mann, Mark, Mille, Patrick, Miner, Martin M, Morgan, Todd, Moreno, Jose, Mucci, Lorelei, Myers, Ronald E, Nielsen, Sarah M, O'Neil, Brock, Pinover, Wayne, Pinto, Peter, Poage, Wendy, Raj, Ganesh V, Rebbeck, Timothy R, Ryan, Charles, Sandler, Howard, Schiewer, Matthew, Scott, E Michael D, Szymaniak, Brittany, Tester, William, Trabulsi, Edouard J, Vapiwala, Neha, Yu, Evan Y, Zeigler-Johnson, Charnita, and Gomella, Leonard G

Subjects
Biotechnology, Aging, Genetics, Prevention, Clinical Research, Cancer, Prostate Cancer, Genetic Testing, Urologic Diseases, Health Services, Good Health and Well Being, Germ-Line Mutation, History, 20th Century, Humans, Male, Prostatic Neoplasms, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeGermline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services.MethodsA multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider).ResultsLarge germline panels and somatic testing were recommended for metastatic PCA. Reflex testing-initial testing of priority genes followed by expanded testing-was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches.ConclusionThis multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.

Published
2020

6. Low Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples From Clinical Practice.

Author

Gaylis, Franklin, Bree, Kelly K, Dato, Paul, Andriole, Gerald L, Kane, Christopher J, and Kader, A Karim

Subjects
Germline DNA tests, Prostate cancer screening, Risk stratification, Single nucleotide polymorphism DNA test, Somatic DNA test, Genetic Testing, Health Services, Prevention, Aging, Clinical Research, Prostate Cancer, Cancer, Genetics, Urologic Diseases, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, 2.1 Biological and endogenous factors, Aetiology, 4.4 Population screening, Good Health and Well Being
Abstract

Broad-based prostate-specific antigen (PSA) screening has saved lives but at a substantial human and financial cost. One way of mitigating this harm, while maintaining and possibly improving the benefit, is by focusing screening efforts on men at higher risk. With age, race, and family history as the only risk factors, many men lack any reliable data to inform their prostate cancer (PCa) screening decisions. Complexities including history of previous negative biopsies, interpretation of negative and/or equivocal mpMRI findings, and patient comorbidities further compound the already complicated decisions surrounding PCa screening and early detection. The authors present cases that provide real-world examples of how a single nucleotide polymorphism-based test can provide patients and providers with personalized PCa risk assessments and allow for development of improved risk-stratified screening regimens.

Published
2020

10. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Author

Schumacher, Fredrick R, Al Olama, Ali Amin, Berndt, Sonja I, Benlloch, Sara, Ahmed, Mahbubl, Saunders, Edward J, Dadaev, Tokhir, Leongamornlert, Daniel, Anokian, Ezequiel, Cieza-Borrella, Clara, Goh, Chee, Brook, Mark N, Sheng, Xin, Fachal, Laura, Dennis, Joe, Tyrer, Jonathan, Muir, Kenneth, Lophatananon, Artitaya, Stevens, Victoria L, Gapstur, Susan M, Carter, Brian D, Tangen, Catherine M, Goodman, Phyllis J, Thompson, Ian M, Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Clements, Judith, Horvath, Lisa, Tilley, Wayne, Risbridger, Gail P, Gronberg, Henrik, Aly, Markus, Nordström, Tobias, Pharoah, Paul, Pashayan, Nora, Schleutker, Johanna, Tammela, Teuvo LJ, Sipeky, Csilla, Auvinen, Anssi, Albanes, Demetrius, Weinstein, Stephanie, Wolk, Alicja, Håkansson, Niclas, West, Catharine ML, Dunning, Alison M, Burnet, Neil, Mucci, Lorelei A, Giovannucci, Edward, Andriole, Gerald L, Cussenot, Olivier, Cancel-Tassin, Géraldine, Koutros, Stella, Beane Freeman, Laura E, Sorensen, Karina Dalsgaard, Orntoft, Torben Falck, Borre, Michael, Maehle, Lovise, Grindedal, Eli Marie, Neal, David E, Donovan, Jenny L, Hamdy, Freddie C, Martin, Richard M, Travis, Ruth C, Key, Tim J, Hamilton, Robert J, Fleshner, Neil E, Finelli, Antonio, Ingles, Sue Ann, Stern, Mariana C, Rosenstein, Barry S, Kerns, Sarah L, Ostrer, Harry, Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Guo, Xin, Wang, Guomin, Sun, Zan, Giles, Graham G, Southey, Melissa C, MacInnis, Robert J, FitzGerald, Liesel M, Kibel, Adam S, Drake, Bettina F, Vega, Ana, Gómez-Caamaño, Antonio, Szulkin, Robert, Eklund, Martin, Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Penney, Kathryn L, Stampfer, Meir, Park, Jong Y, Sellers, Thomas A, Lin, Hui-Yi, Stanford, Janet L, and Cybulski, Cezary

Subjects
Cancer, Aging, Prostate Cancer, Genetics, Urologic Diseases, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Case-Control Studies, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Male, Polymorphism, Single Nucleotide, Prostatic Neoplasms, Risk, Profile Study, Australian Prostate Cancer BioResource, IMPACT Study, Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Cancer of the Prostate in Sweden, Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci, Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10-9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55-2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04-6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa1.

Published
2018

11. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Author

Giri, Veda N, Knudsen, Karen E, Kelly, William K, Abida, Wassim, Andriole, Gerald L, Bangma, Chris H, Bekelman, Justin E, Benson, Mitchell C, Blanco, Amie, Burnett, Arthur, Catalona, William J, Cooney, Kathleen A, Cooperberg, Matthew, Crawford, David E, Den, Robert B, Dicker, Adam P, Eggener, Scott, Fleshner, Neil, Freedman, Matthew L, Hamdy, Freddie C, Hoffman-Censits, Jean, Hurwitz, Mark D, Hyatt, Colette, Isaacs, William B, Kane, Christopher J, Kantoff, Philip, Karnes, R Jeffrey, Karsh, Lawrence I, Klein, Eric A, Lin, Daniel W, Loughlin, Kevin R, Lu-Yao, Grace, Malkowicz, S Bruce, Mann, Mark J, Mark, James R, McCue, Peter A, Miner, Martin M, Morgan, Todd, Moul, Judd W, Myers, Ronald E, Nielsen, Sarah M, Obeid, Elias, Pavlovich, Christian P, Peiper, Stephen C, Penson, David F, Petrylak, Daniel, Pettaway, Curtis A, Pilarski, Robert, Pinto, Peter A, Poage, Wendy, Raj, Ganesh V, Rebbeck, Timothy R, Robson, Mark E, Rosenberg, Matt T, Sandler, Howard, Sartor, Oliver, Schaeffer, Edward, Schwartz, Gordon F, Shahin, Mark S, Shore, Neal D, Shuch, Brian, Soule, Howard R, Tomlins, Scott A, Trabulsi, Edouard J, Uzzo, Robert, Vander Griend, Donald J, Walsh, Patrick C, Weil, Carol J, Wender, Richard, and Gomella, Leonard G

Subjects
Humans, Prostatic Neoplasms, Genetic Predisposition to Disease, Prognosis, Risk Factors, Predictive Value of Tests, Pedigree, Age Factors, Heredity, Phenotype, Adult, Aged, Middle Aged, Male, Genetic Testing, Biomarkers, Tumor, Clinical Decision-Making, Genetics, Aging, Cancer, Prevention, Prostate Cancer, Urologic Diseases, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited PCA in the multigene testing era addressing genetic counseling, testing, and genetically informed management. Methods An expert consensus conference was convened including key stakeholders to address genetic counseling and testing, PCA screening, and management informed by evidence review. Results Consensus was strong that patients should engage in shared decision making for genetic testing. There was strong consensus to test HOXB13 for suspected hereditary PCA, BRCA1/2 for suspected hereditary breast and ovarian cancer, and DNA mismatch repair genes for suspected Lynch syndrome. There was strong consensus to factor BRCA2 mutations into PCA screening discussions. BRCA2 achieved moderate consensus for factoring into early-stage management discussion, with stronger consensus in high-risk/advanced and metastatic setting. Agreement was moderate to test all men with metastatic castration-resistant PCA, regardless of family history, with stronger agreement to test BRCA1/2 and moderate agreement to test ATM to inform prognosis and targeted therapy. Conclusion To our knowledge, this is the first comprehensive, multidisciplinary consensus statement to address a genetic evaluation framework for inherited PCA in the multigene testing era. Future research should focus on developing a working definition of familial PCA for clinical genetic testing, expanding understanding of genetic contribution to aggressive PCA, exploring clinical use of genetic testing for PCA management, genetic testing of African American males, and addressing the value framework of genetic evaluation and testing men at risk for PCA-a clinically heterogeneous disease.

Published
2018

12. Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development

Author

Barashi, Nimrod S., primary, Li, Tiandao, additional, Angappulige, Duminduni H., additional, Zhang, Bo, additional, O’Gorman, Harry, additional, Nottingham, Charles U., additional, Shetty, Anup S., additional, Ippolito, Joseph E., additional, Andriole, Gerald L., additional, Mahajan, Nupam P., additional, Kim, Eric H., additional, and Mahajan, Kiran, additional

Published
2024
Full Text
View/download PDF

13. Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis

Author

Roy, Amit, Brenneman, Randall J., Hogan, Jacob, Barnes, Justin M., Huang, Yi, Morris, Robert, Goddu, Sreekrishna, Altman, Michael, Garcia-Ramirez, Jose, Li, Harold, Zoberi, Jacqueline E., Bullock, Arnold, Kim, Eric, Smith, Zachary, Figenshau, Robert, Andriole, Gerald L., Baumann, Brian C., Michalski, Jeff M., and Gay, Hiram A.

Published
2021
Full Text
View/download PDF

14. Symptom Variability and Early Symptom Regression in the MAPP Study: A Prospective Study of Urological Chronic Pelvic Pain Syndrome

Author

Stephens-Shields, Alisa J, Clemens, J Quentin, Jemielita, Thomas, Farrar, John, Sutcliffe, Siobhan, Hou, Xiaoling, Landis, J Richard, Hanno, Philip, Kirkali, Ziya, Kusek, John W, Lucia, M Scott, Moldwin, Robert M, Mullins, Chris, Pontari, Michel A, Klumpp, David J, Schaeffer, Anthony J, Apkarian, Apkar, Cella, David, Farmer, Melissa A, Fitzgerald, Colleen, Gershon, Richard, Griffith, James W, Heckman, Charles J, Jiang, Mingchen, Keefer, Laurie, Marko, Darlene S, Michniewicz, Jean, Parrish, Todd, Tu, Frank, Mayer, Emeran A, Rodríguez, Larissa V, Alger, Jeffry, Ashe-McNalley, Cody P, Ellingson, Ben, Heendeniya, Nuwanthi, Kilpatrick, Lisa, Kulbacki, Cara, Kutch, Jason, Labus, Jennifer S, Naliboff, Bruce D, Randal, Fornessa, Smith, Suzanne R, Kreder, Karl J, Bradley, Catherine S, Eno, Mary, Greiner, Kris, Luo, Yi, Lutgendorf, Susan K, O’Donnell, Michael A, Ziegler, Barbara, Clauw, Daniel J, As-Sanie, Suzie, Berry, Sandra, Grayhack, Clara, Halvorson, Megan E, Harris, Richard, Harte, Steve, Ichesco, Eric, Oldendorf, Ann, Scott, Katherine A, Williams, David A, Buchwald, Dedra, Afari, Niloofar, Krieger, John, Miller, Jane, Richey, Stephanie, Robertson, Kelly, Ross, Susan O, Spiro, Roberta, Sundsvold, TJ, Strachan, Eric, Yang, Claire C, Andriole, Gerald L, Lai, H Henry, Bristol, Rebecca L, Colditz, Graham, Deutsch, Georg, Gardner, Vivien C, Gereau, Robert W, Henderson, Jeffrey P, Hong, Barry A, Hooton, Thomas M, Ness, Timothy J, North, Carol S, Spitznagle, Theresa M, Anger, Jennifer, Freeman, Michael, Kim, Jayoung, Eilber, Karyn, Van Eyk, Jennifer, Yang, Wei, Funari, Vincent, Cha, Jeena, and Barrell, Ted

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Chronic Pain, Pain Research, Clinical Research, Urologic Diseases, Adult, Female, Humans, Male, Prospective Studies, Prostatitis, Symptom Assessment, Time Factors, MAPP Research Network, cystitis, epidemiologic research design, interstitial, pain, prostate, symptom assessment
Abstract

PurposeWe examined symptom variability in men and women with urological chronic pelvic pain syndrome. We describe symptom fluctuations as related to early symptom regression and its effect on estimated 1-year symptom change. We also describe a method to quantify patient specific symptom variability.Materials and methodsSymptoms were assessed biweekly in 424 subjects with urological chronic pelvic pain syndrome during 1 year. To evaluate the impact of early symptom regression subjects were classified as improved, no change or worse according to the rate of change using 1) all data, 2) excluding week 0 and 3) excluding weeks 0 and 2. Patient specific, time varying variability was calculated at each interval using a sliding window approach. Patients were classified as high, medium or low variability at each time and ultimately as high or low variability overall based on the variability for the majority of contacts.ResultsPrior to excluding early weeks to adjust for early symptom regression 25% to 38% and 5% to 6% of patients were classified as improved and worse, respectively. After adjustment the percent of patients who were improved or worse ranged from 15% to 25% and 6% to 9%, respectively. High and low variability phenotypes were each identified in 25% to 30% of participants.ConclusionsPatients with urological chronic pelvic pain syndrome show symptom variability. At study enrollment patients had worse symptoms on average, resulting in a regression effect that influenced the estimated proportion of those who were improved or worse. Prospective studies should include a run-in period to account for regression to the mean and other causes of early symptom regression. Further, symptom variability may be quantified and used to characterize longitudinal symptom profiles of urological chronic pelvic pain syndrome.

Published
2016

16. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

Author

Conti, David V., Darst, Burcu F., Moss, Lilit C., Saunders, Edward J., Sheng, Xin, Chou, Alisha, Schumacher, Fredrick R., Olama, Ali Amin Al, Benlloch, Sara, Dadaev, Tokhir, Brook, Mark N., Sahimi, Ali, Hoffmann, Thomas J., Takahashi, Atushi, Matsuda, Koichi, Momozawa, Yukihide, Fujita, Masashi, Muir, Kenneth, Lophatananon, Artitaya, Wan, Peggy, Le Marchand, Loic, Wilkens, Lynne R., Stevens, Victoria L., Gapstur, Susan M., Carter, Brian D., Schleutker, Johanna, Tammela, Teuvo L. J., Sipeky, Csilla, Auvinen, Anssi, Giles, Graham G., Southey, Melissa C., MacInnis, Robert J., Cybulski, Cezary, Wokołorczyk, Dominika, Lubiński, Jan, Neal, David E., Donovan, Jenny L., Hamdy, Freddie C., Martin, Richard M., Nordestgaard, Børge G., Nielsen, Sune F., Weischer, Maren, Bojesen, Stig E., Røder, Martin Andreas, Iversen, Peter, Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Horvath, Lisa, Clements, Judith A., Tilley, Wayne, Risbridger, Gail P., Gronberg, Henrik, Aly, Markus, Szulkin, Robert, Eklund, Martin, Nordström, Tobias, Pashayan, Nora, Dunning, Alison M., Ghoussaini, Maya, Travis, Ruth C., Key, Tim J., Riboli, Elio, Park, Jong Y., Sellers, Thomas A., Lin, Hui-Yi, Albanes, Demetrius, Weinstein, Stephanie J., Mucci, Lorelei A., Giovannucci, Edward, Lindstrom, Sara, Kraft, Peter, Hunter, David J., Penney, Kathryn L., Turman, Constance, Tangen, Catherine M., Goodman, Phyllis J., Thompson, Jr., Ian M., Hamilton, Robert J., Fleshner, Neil E., Finelli, Antonio, Parent, Marie-Élise, Stanford, Janet L., Ostrander, Elaine A., Geybels, Milan S., Koutros, Stella, Freeman, Laura E. Beane, Stampfer, Meir, Wolk, Alicja, Håkansson, Niclas, Andriole, Gerald L., Hoover, Robert N., Machiela, Mitchell J., Sørensen, Karina Dalsgaard, Borre, Michael, Blot, William J., Zheng, Wei, Yeboah, Edward D., Mensah, James E., Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Wu, Yudong, Zhao, Shan-Chao, Sun, Zan, Thibodeau, Stephen N., McDonnell, Shannon K., Schaid, Daniel J., West, Catharine M. L., Burnet, Neil, Barnett, Gill, Maier, Christiane, Schnoeller, Thomas, Luedeke, Manuel, Kibel, Adam S., Drake, Bettina F., Cussenot, Olivier, Cancel-Tassin, Géraldine, Menegaux, Florence, Truong, Thérèse, Koudou, Yves Akoli, John, Esther M., Grindedal, Eli Marie, Maehle, Lovise, Khaw, Kay-Tee, Ingles, Sue A., Stern, Mariana C., Vega, Ana, Gómez-Caamaño, Antonio, Fachal, Laura, Rosenstein, Barry S., Kerns, Sarah L., Ostrer, Harry, Teixeira, Manuel R., Paulo, Paula, Brandão, Andreia, Watya, Stephen, Lubwama, Alexander, Bensen, Jeannette T., Fontham, Elizabeth T. H., Mohler, James, Taylor, Jack A., Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Cannon-Albright, Lisa, Teerlink, Craig C., Huff, Chad D., Strom, Sara S., Multigner, Luc, Blanchet, Pascal, Brureau, Laurent, Kaneva, Radka, Slavov, Chavdar, Mitev, Vanio, Leach, Robin J., Weaver, Brandi, Brenner, Hermann, Cuk, Katarina, Holleczek, Bernd, Saum, Kai-Uwe, Klein, Eric A., Hsing, Ann W., Kittles, Rick A., Murphy, Adam B., Logothetis, Christopher J., Kim, Jeri, Neuhausen, Susan L., Steele, Linda, Ding, Yuan Chun, Isaacs, William B., Nemesure, Barbara, Hennis, Anselm J. M., Carpten, John, Pandha, Hardev, Michael, Agnieszka, De Ruyck, Kim, De Meerleer, Gert, Ost, Piet, Xu, Jianfeng, Razack, Azad, Lim, Jasmine, Teo, Soo-Hwang, Newcomb, Lisa F., Lin, Daniel W., Fowke, Jay H., Neslund-Dudas, Christine, Rybicki, Benjamin A., Gamulin, Marija, Lessel, Davor, Kulis, Tomislav, Usmani, Nawaid, Singhal, Sandeep, Parliament, Matthew, Claessens, Frank, Joniau, Steven, Van den Broeck, Thomas, Gago-Dominguez, Manuela, Castelao, Jose Esteban, Martinez, Maria Elena, Larkin, Samantha, Townsend, Paul A., Aukim-Hastie, Claire, Bush, William S., Aldrich, Melinda C., Crawford, Dana C., Srivastava, Shiv, Cullen, Jennifer C., Petrovics, Gyorgy, Casey, Graham, Roobol, Monique J., Jenster, Guido, van Schaik, Ron H. N., Hu, Jennifer J., Sanderson, Maureen, Varma, Rohit, McKean-Cowdin, Roberta, Torres, Mina, Mancuso, Nicholas, Berndt, Sonja I., Van Den Eeden, Stephen K., Easton, Douglas F., Chanock, Stephen J., Cook, Michael B., Wiklund, Fredrik, Nakagawa, Hidewaki, Witte, John S., Eeles, Rosalind A., Kote-Jarai, Zsofia, and Haiman, Christopher A.

Published
2021
Full Text
View/download PDF

17. 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE

Author

Adler, Lee P., Andriole, Gerald L., Belkoff, Laurence H., Burzon, Daniel, Chau, Albert, Dato, Paul, Duan, Fenghai, Farwell, Michael, Fogelson, Stephen, Gardiner, Peter, Hanna, Lucy, Hoffman, John M., Intenzo, Charles, Josephson, David, Kaminetsky, Jed, Kipper, Michael, Kostakoglu, Lale, Krynyckyi, Borys, Linder, Karen E., Mahmood, Umar, Marques, Helga, Mankoff, David, McConathy, Jonathan, Melnick, John, Miller, Matthew P., Oh, William, Philips, Shaile, Rose, Judith, Savir-Baruch, Bital, Schuster, David M., Siegel, Barry A., Stevens, Daniel J., Tewari, Ashutosh, Twardowski, Przemyslaw, Ward, Penelope, Wasserman, Martha, Weick, Sharon, (Michael) Yu, Jian Q., Solanki, Abhishek A., Liauw, Stanley L., Michalski, Jeff, Tward, Jonathan D., Vapiwala, Neha, and Teoh, Eugene J.

Published
2020
Full Text
View/download PDF

19. Prostate MRI: a national survey of Urologist’s attitudes and perceptions

Author

Manley, Brandon J, Brockman, John A, Raup, Valary T, Fowler, Kathryn J, and Andriole, Gerald L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Biomedical Imaging, Cancer, Prostate Cancer, Clinical Research, Urologic Diseases, Biopsy, Humans, Magnetic Resonance Imaging, Male, Practice Patterns, Physicians', Prostate, Prostatectomy, Prostatic Neoplasms, Surveys and Questionnaires, United States, Urologists, Urology & Nephrology
Abstract

IntroductionThe use of multi-parametric (MP) MRI to diagnose prostate cancer has been the subject of intense research, with many studies showing positive results. The purpose of our study is to better understand the accessibility, role, and perceived accuracy of MP-MRI in practice by surveying practicing urologists.Materials and methodsSurveys were sent to 7,400 practicing American Urological Association member physicians with a current email address. The survey asked demographic information and addressed access, accuracy, cost, and role of prostate MRI in clinical practice.ResultsOur survey elicited 276 responses. Respondents felt that limited access and prohibitive cost of MP-MRI limits its use, 72% and 59% respectively. Academic urologists ordered more MP-MRI studies per year than those in private practice (43.3% vs. 21.1%; p

Published
2016

20. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom‐related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Author

Breyer, Benjamin N, Huang, Wen-Yi, Rabkin, Charles S, Alderete, John F, Pakpahan, Ratna, Beason, Tracey S, Kenfield, Stacey A, Mabie, Jerome, Ragard, Lawrence, Wolin, Kathleen Y, Grubb, Robert L, Andriole, Gerald L, and Sutcliffe, Siobhan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Sexually Transmitted Infections, Urologic Diseases, Cancer, Infectious Diseases, Prevention, Infection, Good Health and Well Being, Aged, Humans, Incidence, Lower Urinary Tract Symptoms, Male, Middle Aged, Prevalence, Prospective Studies, Prostatic Hyperplasia, Retrospective Studies, Sexually Transmitted Diseases, sexually transmitted infection, benign prostatic hyperplasia, nocturia, Prostate lung colorectal and ovarian cancer screening trial, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

ObjectiveTo examine whether a history of sexually transmitted infections (STIs) or positive STI serology is associated with prevalent and incident benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS)-related outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.MethodsSelf-reported history of STIs (gonorrhoea, syphilis) was ascertained at baseline, and serological evidence of STIs (Chlamydia trachomatis, Trichomonas vaginalis, human papillomavirus (HPV)-16, HPV-18, herpes simplex virus type 2, human herpesvirus type 8 and cytomegalovirus) was detected in baseline serum specimens. We used data collected on the baseline questionnaire, as well as results from the baseline prostate-specific antigen (PSA) test and digital rectal examination (DRE), to define prevalent BPH/LUTS-related outcomes as evidence of LUTS (self-reported diagnosis of an enlarged prostate/BPH, BPH surgery or nocturia [waking ≥2 times/night to urinate]) and evidence of prostate enlargement (PSA > 1.4 ng/mL or prostate volume ≥30 mL) in men without prostate cancer. We created a similar definition of incident BPH using data from the follow-up questionnaire completed 5-13 years after enrolment (self-reported diagnosis of an enlarged prostate/BPH or nocturia), data on finasteride use during follow-up, and results from the follow-up PSA tests and DREs. We used Poisson regression with robust variance estimation to calculate prevalence ratios (PRs) in our cross-sectional analysis of self-reported (n = 32 900) and serologically detected STIs (n = 1 143) with prevalent BPH/LUTS, and risk ratios in our prospective analysis of self-reported STIs with incident BPH/LUTS (n = 5 226).ResultsGenerally null results were observed for associations of a self-reported history of STIs and positive STI serologies with prevalent and incident BPH/LUTS-related outcomes, with the possible exception of T. vaginalis infection. This STI was positively associated with prevalent nocturia (PR 1.36, 95% confidence interval (CI) 1.18-1.65), prevalent large prostate volume (PR 1.21 95% CI 1.02-1.43), and any prevalent BPH/LUTS (PR 1.32 95% CI 1.09-1.61); too few men had information on both STI serologies and incident BPH/LUTS to investigate the associations between T. vaginalis infection and incident BPH/LUTS-related outcomes.ConclusionsOur findings do not support associations of several known STIs with BPH/LUTS-related outcomes, although T. vaginalis infection may warrant further study.

Published
2016

21. Relationship between Chronic Nonurological Associated Somatic Syndromes and Symptom Severity in Urological Chronic Pelvic Pain Syndromes: Baseline Evaluation of the MAPP Study

Author

Krieger, John N, Stephens, Alisa J, Landis, J Richard, Clemens, J Quentin, Kreder, Karl, Lai, H Henry, Afari, Niloofar, Rodríguez, Larissa, Schaeffer, Anthony, Mackey, Sean, Andriole, Gerald L, Williams, David A, Hanno, Philip, Kirkali, Ziya, Kusek, John W, Lucia, M Scott, Mullins, Chris, Pontari, Michel A, Klumpp, David J, Schaeffer, Anthony J, Apkarian, Apkar, Cella, David, Farmer, Melissa A, Fitzgerals, Colleen, Gershon, Richard, Griffith, James W, Heckman, Charles J, Jiang, Mingchen, Keeper, Laurie, Parrish, Todd, Tu, Frank, Marko, Darlene S, Mayer, Emeran A, Rodríguez, Larissa V, Alger, Jeffry, Ashe-McNalley, Cody P, Ellingson, Ben, Kilpatrick, Lisa, Kutch, Jason, Labus, Jennifer S, Naliboff, Bruce D, Heendeniya, Nuwanthi, Randal, Fornessa, Smith, Suzanne R, Kreder, Karl J, Bradley, Catherine S, Luo, Yi, Lutgendorf, Susan K, O'Donnell, Michael A, Eno, Mary, Greiner, Kris, Ziegler, Barbara, Clauw, Daniel J, As-Sanie, Suzie, Harris, Richard, Harte, Steve, Oldendorf, Ann, Berry, Sandra, Halvorson, Megan E, Ichesco, Eric, Scott, Katherine A, Buchwald, Dedra, Krieger, John, Miller, Jane, Strachan, Eric, Yang, Claire C, Richey, Stephanie, Ross, Susan O, Spiro, Roberta, Sundsvold, TJ, Bristol, Rebecca L, Gardner, Vivien C, Colditz, Graham, Deutsch, Georg, Gereau, Robert W, Henderson, Jeffrey P, Hone, Barry A, Hooton, Thomas M, Ness, Timothy J, North, Carol S, Sutcliffe, Siobhan, Spitznagle, Theresa M, Robinson, Nancy, Stephens, Alisa, Barrell, Ted, Hou, Xiaoling, Howard, Tamara, Wang, Yanli, and van Bokhoven, Andrie

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Depression, Urologic Diseases, Chronic Pain, Mental Health, Pain Research, Management of diseases and conditions, 7.1 Individual care needs, Chronic Disease, Cross-Sectional Studies, Cystitis, Interstitial, Female, Humans, Interdisciplinary Communication, Male, Pelvic Pain, Severity of Illness Index, Surveys and Questionnaires, Symptom Assessment, Syndrome, urinary bladder, cystitis, interstitial, male, female, questionnaires, MAPP Research Network
Abstract

PurposeWe used MAPP data to identify participants with urological chronic pelvic pain syndromes only or a chronic functional nonurological associated somatic syndrome in addition to urological chronic pelvic pain syndromes. We characterized these 2 subgroups and explored them using 3 criteria, including 1) MAPP eligibility criteria, 2) self-reported medical history or 3) RICE criteria.Materials and methodsSelf-reported cross-sectional data were collected on men and women with urological chronic pelvic pain syndromes, including predominant symptoms, symptom duration and severity, nonurological associated somatic syndrome symptoms and psychosocial factors.ResultsOf 424 participants with urological chronic pelvic pain syndromes 162 (38%) had a nonurological associated somatic syndrome, including irritable bowel syndrome in 93 (22%), fibromyalgia in 15 (4%), chronic fatigue syndrome in 13 (3%) and multiple syndromes in 41 (10%). Of 233 females 103 (44%) had a nonurological associated somatic syndrome compared to 59 of 191 males (31%) (p = 0.006). Participants with a nonurological associated somatic syndrome had more severe urological symptoms and more frequent depression and anxiety. Of 424 participants 228 (54%) met RICE criteria. Of 228 RICE positive participants 108 (47%) had a nonurological associated somatic syndrome compared to 54 of 203 RICE negative patients (28%) with a nonurological associated somatic syndrome (p < 0.001).ConclusionsNonurological associated somatic syndromes represent important clinical characteristics of urological chronic pelvic pain syndromes. Participants with a nonurological associated somatic syndrome have more severe symptoms, longer duration and higher rates of depression and anxiety. RICE positive patients are more likely to have a nonurological associated somatic syndrome and more severe symptoms. Because nonurological associated somatic syndromes are more common in women, future studies must account for this potential confounding factor in urological chronic pelvic pain syndromes.

Published
2015

22. The MAPP research network: a novel study of urologic chronic pelvic pain syndromes

Author

Clemens, J Quentin, Mullins, Chris, Kusek, John W, Kirkali, Ziya, Mayer, Emeran A, Rodríguez, Larissa V, Klumpp, David J, Schaeffer, Anthony J, Kreder, Karl J, Buchwald, Dedra, Andriole, Gerald L, Lucia, M Scott, Landis, J Richard, Clauw, Daniel J, and The MAPP Research Network Study Group

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Interstitial Cystitis, Clinical Research, Pain Research, Chronic Pain, Urologic Diseases, 2.1 Biological and endogenous factors, Aetiology, Renal and urogenital, Biomedical Research, Chronic Disease, Cystitis, Interstitial, Humans, Interdisciplinary Communication, Male, National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), Pelvic Pain, Prostatitis, Syndrome, United States, Urological chronic pelvic pain syndromes, Interstitial cystitis, Chronic prostatitis, Translational research, Multi-disciplinary, MAPP Research Network Study Group, Urology & Nephrology, Clinical sciences
Abstract

UnlabelledUrologic chronic pelvic pain syndrome (UCPPS) may be defined to include interstitial cystitis/bladder pain syndrome (IC/BPS) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The hallmark symptom of UCPPS is chronic pain in the pelvis, urogenital floor, or external genitalia often accompanied by lower urinary tract symptoms. Despite numerous past basic and clinical research studies there is no broadly identifiable organ-specific pathology or understanding of etiology or risk factors for UCPPS, and diagnosis relies primarily on patient reported symptoms. In addition, there are no generally effective therapies. Recent findings have, however, revealed associations between UCPPS and "centralized" chronic pain disorders, suggesting UCPPS may represent a local manifestation of more widespread pathology in some patients. Here, we describe a new and novel effort initiated by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the U.S. National Institutes of Health (NIH) to address the many long standing questions regarding UCPPS, the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. The MAPP Network approaches UCPPS in a systemic manner, in which the interplay between the genitourinary system and other physiological systems is emphasized. The network's study design expands beyond previous research, which has primarily focused on urologic organs and tissues, to utilize integrated approaches to define patient phenotypes, identify clinically-relevant subgroups, and better understand treated natural history and pathophysiology. Thus, the MAPP Network provides an unprecedented, multi-layered characterization of UCPPS. Knowledge gained is expected to provide important insights into underlying pathophysiology, a foundation for better segmenting patients for future clinical trials, and ultimately translation into improved clinical management. In addition, the MAPP Network's integrated multi-disciplinary research approach may serve as a model for studies of urologic and non-urologic disorders that have proven refractory to past basic and clinical study.Trial registrationClinicalTrials.gov identifier: NCT01098279 "Chronic Pelvic Pain Study of Individuals with Diagnoses or Symptoms of Interstitial Cystitis and/or Chronic Prostatitis (MAPP-EP)".

Published
2014

23. The MAPP research network: design, patient characterization and operations

Author

Landis, J Richard, Williams, David A, Lucia, M Scott, Clauw, Daniel J, Naliboff, Bruce D, Robinson, Nancy A, van Bokhoven, Adrie, Sutcliffe, Siobhan, Schaeffer, Anthony J, Rodriguez, Larissa V, Mayer, Emeran A, Lai, H Henry, Krieger, John N, Kreder, Karl J, Afari, Niloofar, Andriole, Gerald L, Bradley, Catherine S, Griffith, James W, Klumpp, David J, Hong, Barry A, Lutgendorf, Susan K, Buchwald, Dedra, Yang, Claire C, Mackey, Sean, Pontari, Michel A, Hanno, Philip, Kusek, John W, Mullins, Chris, Clemens, J Quentin, and The MAPP Research Network Study Group

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Fibromyalgia, Pain Research, Chronic Pain, Clinical Research, Urologic Diseases, Women's Health, Neurosciences, 2.1 Biological and endogenous factors, Good Health and Well Being, Biomedical Research, Chronic Disease, Cystitis, Interstitial, Female, Humans, Interdisciplinary Communication, Longitudinal Studies, Male, National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), Pelvic Pain, Phenotype, Prospective Studies, Prostatitis, Research Design, Syndrome, United States, Urologic chronic pelvic pain syndromes, Interstitial cystitis, Chronic prostatitis, Urine biomarkers, Plasma biomarkers, Non-urologic associated syndromes, Quantitative sensory testing, Neuroimaging, MAPP Research Network Study Group, Urology & Nephrology, Clinical sciences
Abstract

BackgroundThe "Multidisciplinary Approach to the Study of Chronic Pelvic Pain" (MAPP) Research Network was established by the NIDDK to better understand the pathophysiology of urologic chronic pelvic pain syndromes (UCPPS), to inform future clinical trials and improve clinical care. The evolution, organization, and scientific scope of the MAPP Research Network, and the unique approach of the network's central study and common data elements are described.MethodsThe primary scientific protocol for the Trans-MAPP Epidemiology/Phenotyping (EP) Study comprises a multi-site, longitudinal observational study, including bi-weekly internet-based symptom assessments, following a comprehensive in-clinic deep-phenotyping array of urological symptoms, non-urological symptoms and psychosocial factors to evaluate men and women with UCPPS. Healthy controls, matched on sex and age, as well as "positive" controls meeting the non-urologic associated syndromes (NUAS) criteria for one or more of the target conditions of Fibromyalgia (FM), Chronic Fatigue Syndrome (CFS) or Irritable Bowel Syndrome (IBS), were also evaluated. Additional, complementary studies addressing diverse hypotheses are integrated into the Trans-MAPP EP Study to provide a systemic characterization of study participants, including biomarker discovery studies of infectious agents, quantitative sensory testing, and structural and resting state neuroimaging and functional neurobiology studies. A highly novel effort to develop and assess clinically relevant animal models of UCPPS was also undertaken to allow improved translation between clinical and mechanistic studies. Recruitment into the central study occurred at six Discovery Sites in the United States, resulting in a total of 1,039 enrolled participants, exceeding the original targets. The biospecimen collection rate at baseline visits reached nearly 100%, and 279 participants underwent common neuroimaging through a standardized protocol. An extended follow-up study for 161 of the UCPPS participants is ongoing.DiscussionThe MAPP Research Network represents a novel, comprehensive approach to the study of UCPPS, as well as other concomitant NUAS. Findings are expected to provide significant advances in understanding UCPPS pathophysiology that will ultimately inform future clinical trials and lead to improvements in patient care. Furthermore, the structure and methodologies developed by the MAPP Network provide the foundation upon which future studies of other urologic or non-urologic disorders can be based.Trial registrationClinicalTrials.gov identifier: NCT01098279 "Chronic Pelvic Pain Study of Individuals with Diagnoses or Symptoms of Interstitial Cystitis and/or Chronic Prostatitis (MAPP-EP)". http://clinicaltrials.gov/show/NCT01098279.

Published
2014

26. Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT

Author

Ditonno, Francesco, primary, Franco, Antonio, additional, Manfredi, Celeste, additional, Veccia, Alessandro, additional, Valerio, Massimo, additional, Bukavina, Laura, additional, Zukowski, Lucas B., additional, Vourganti, Srinivas, additional, Stenzl, Arnuf, additional, Andriole, Gerald L., additional, Antonelli, Alessandro, additional, De Nunzio, Cosimo, additional, and Autorino, Riccardo, additional

Published
2023
Full Text
View/download PDF

27. A Case-Crossover Study of Urological Chronic Pelvic Pain Syndrome Flare Triggers in the MAPP Research Network

Author

Sutcliffe, Siobhan, Jemielita, Thomas, Lai, H. Henry, Andriole, Gerald L., Bradley, Catherine S., Clemens, J. Quentin, Gallop, Robert, Hooton, Thomas M., Kreder, Karl J., Krieger, John N., Kusek, John W., Labus, Jennifer, Lucia, M. Scott, Mackey, Sean, Naliboff, Bruce D., Robinson, Nancy A., Rodriguez, Larissa V., Stephens-Shields, Alisa, van Bokhoven, Adrie, Wolin, Kathleen Y., Yan, Yan, Yang, Claire C., Landis, J. Richard, and Colditz, Graham A.

Published
2018
Full Text
View/download PDF

45. Supplementary notes from Genome-Wide Association Study of Prostate Cancer–Specific Survival

Author

Szulkin, Robert, primary, Karlsson, Robert, primary, Whitington, Thomas, primary, Aly, Markus, primary, Gronberg, Henrik, primary, Eeles, Rosalind A., primary, Easton, Douglas F., primary, Kote-Jarai, Zsofia, primary, Al Olama, Ali Amin, primary, Benlloch, Sara, primary, Muir, Kenneth, primary, Giles, Graham G., primary, Southey, Melissa C., primary, FitzGerald, Liesel M., primary, Henderson, Brian E., primary, Schumacher, Fredrick R., primary, Haiman, Christopher A., primary, Sipeky, Csilla, primary, Tammela, Teuvo L.J., primary, Nordestgaard, Børge G., primary, Key, Timothy J., primary, Travis, Ruth C., primary, Neal, David E., primary, Donovan, Jenny L., primary, Hamdy, Freddie C., primary, Pharoah, Paul D.P., primary, Pashayan, Nora, primary, Khaw, Kay-Tee, primary, Stanford, Janet L., primary, Thibodeau, Stephen N., primary, McDonnell, Shannon K., primary, Schaid, Daniel J., primary, Maier, Christiane, primary, Vogel, Walther, primary, Luedeke, Manuel, primary, Herkommer, Kathleen, primary, Kibel, Adam S., primary, Cybulski, Cezary, primary, Lubiński, Jan, primary, Kluźniak, Wojciech, primary, Cannon-Albright, Lisa, primary, Brenner, Hermann, primary, Herrmann, Volker, primary, Holleczek, Bernd, primary, Park, Jong Y., primary, Sellers, Thomas A., primary, Lim, Hui-Yi, primary, Slavov, Chavdar, primary, Kaneva, Radka P., primary, Mitev, Vanio I., primary, Spurdle, Amanda, primary, Teixeira, Manuel R., primary, Paulo, Paula, primary, Maia, Sofia, primary, Pandha, Hardev, primary, Michael, Agnieszka, primary, Kierzek, Andrzej, primary, Batra, Jyotsna, primary, Clements, Judith A., primary, Albanes, Demetrius, primary, Andriole, Gerald L., primary, Berndt, Sonja I., primary, Chanock, Stephen, primary, Gapstur, Susan M., primary, Giovannucci, Edward L., primary, Hunter, David J., primary, Kraft, Peter, primary, Le Marchand, Loic, primary, Ma, Jing, primary, Mondul, Alison M., primary, Penney, Kathryn L., primary, Stampfer, Meir J., primary, Stevens, Victoria L., primary, Weinstein, Stephanie J., primary, Trichopoulou, Antonia, primary, Bueno-de-Mesquita, Bas H., primary, Tjønneland, Anne, primary, Cox, David G., primary, Maehle, Lovise, primary, Schleutker, Johanna, primary, Lindström, Sara, primary, and Wiklund, Fredrik, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 3 from Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2

Author

Prokunina-Olsson, Ludmila, primary, Fu, Yi-Ping, primary, Tang, Wei, primary, Jacobs, Kevin B., primary, Hayes, Richard B., primary, Kraft, Peter, primary, Berndt, Sonja I., primary, Wacholder, Sholom, primary, Yu, Kai, primary, Hutchinson, Amy, primary, Spencer Feigelson, Heather, primary, Thun, Michael J., primary, Diver, W. Ryan, primary, Albanes, Demetrius, primary, Virtamo, Jarmo, primary, Weinstein, Stephanie, primary, Schumacher, Fredrick R., primary, Cancel-Tassin, Geraldine, primary, Cussenot, Olivier, primary, Valeri, Antoine, primary, Andriole, Gerald L., primary, Crawford, E. David, primary, Haiman, Christopher A., primary, Henderson, Brian E., primary, Kolonel, Laurence, primary, Le Marchand, Loic, primary, Siddiq, Afshan, primary, Riboli, Elio, primary, Travis, Ruth, primary, Kaaks, Rudolf, primary, Isaacs, William B., primary, Isaacs, Sarah D., primary, Grönberg, Henrik, primary, Wiklund, Fredrik, primary, Xu, Jianfeng, primary, Vatten, Lars J., primary, Hveem, Kristian, primary, Kumle, Merethe, primary, Tucker, Margaret, primary, Hoover, Robert N., primary, Fraumeni, Joseph F., primary, Hunter, David J., primary, Thomas, Gilles, primary, Chatterjee, Nilanjan, primary, Chanock, Stephen J., primary, and Yeager, Meredith, primary

Published
2023
Full Text
View/download PDF

47. Data from Genome-Wide Association Study of Prostate Cancer–Specific Survival

Author

Szulkin, Robert, primary, Karlsson, Robert, primary, Whitington, Thomas, primary, Aly, Markus, primary, Gronberg, Henrik, primary, Eeles, Rosalind A., primary, Easton, Douglas F., primary, Kote-Jarai, Zsofia, primary, Al Olama, Ali Amin, primary, Benlloch, Sara, primary, Muir, Kenneth, primary, Giles, Graham G., primary, Southey, Melissa C., primary, FitzGerald, Liesel M., primary, Henderson, Brian E., primary, Schumacher, Fredrick R., primary, Haiman, Christopher A., primary, Sipeky, Csilla, primary, Tammela, Teuvo L.J., primary, Nordestgaard, Børge G., primary, Key, Timothy J., primary, Travis, Ruth C., primary, Neal, David E., primary, Donovan, Jenny L., primary, Hamdy, Freddie C., primary, Pharoah, Paul D.P., primary, Pashayan, Nora, primary, Khaw, Kay-Tee, primary, Stanford, Janet L., primary, Thibodeau, Stephen N., primary, McDonnell, Shannon K., primary, Schaid, Daniel J., primary, Maier, Christiane, primary, Vogel, Walther, primary, Luedeke, Manuel, primary, Herkommer, Kathleen, primary, Kibel, Adam S., primary, Cybulski, Cezary, primary, Lubiński, Jan, primary, Kluźniak, Wojciech, primary, Cannon-Albright, Lisa, primary, Brenner, Hermann, primary, Herrmann, Volker, primary, Holleczek, Bernd, primary, Park, Jong Y., primary, Sellers, Thomas A., primary, Lim, Hui-Yi, primary, Slavov, Chavdar, primary, Kaneva, Radka P., primary, Mitev, Vanio I., primary, Spurdle, Amanda, primary, Teixeira, Manuel R., primary, Paulo, Paula, primary, Maia, Sofia, primary, Pandha, Hardev, primary, Michael, Agnieszka, primary, Kierzek, Andrzej, primary, Batra, Jyotsna, primary, Clements, Judith A., primary, Albanes, Demetrius, primary, Andriole, Gerald L., primary, Berndt, Sonja I., primary, Chanock, Stephen, primary, Gapstur, Susan M., primary, Giovannucci, Edward L., primary, Hunter, David J., primary, Kraft, Peter, primary, Le Marchand, Loic, primary, Ma, Jing, primary, Mondul, Alison M., primary, Penney, Kathryn L., primary, Stampfer, Meir J., primary, Stevens, Victoria L., primary, Weinstein, Stephanie J., primary, Trichopoulou, Antonia, primary, Bueno-de-Mesquita, Bas H., primary, Tjønneland, Anne, primary, Cox, David G., primary, Maehle, Lovise, primary, Schleutker, Johanna, primary, Lindström, Sara, primary, and Wiklund, Fredrik, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Table 2A from Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2

Author

Prokunina-Olsson, Ludmila, primary, Fu, Yi-Ping, primary, Tang, Wei, primary, Jacobs, Kevin B., primary, Hayes, Richard B., primary, Kraft, Peter, primary, Berndt, Sonja I., primary, Wacholder, Sholom, primary, Yu, Kai, primary, Hutchinson, Amy, primary, Spencer Feigelson, Heather, primary, Thun, Michael J., primary, Diver, W. Ryan, primary, Albanes, Demetrius, primary, Virtamo, Jarmo, primary, Weinstein, Stephanie, primary, Schumacher, Fredrick R., primary, Cancel-Tassin, Geraldine, primary, Cussenot, Olivier, primary, Valeri, Antoine, primary, Andriole, Gerald L., primary, Crawford, E. David, primary, Haiman, Christopher A., primary, Henderson, Brian E., primary, Kolonel, Laurence, primary, Le Marchand, Loic, primary, Siddiq, Afshan, primary, Riboli, Elio, primary, Travis, Ruth, primary, Kaaks, Rudolf, primary, Isaacs, William B., primary, Isaacs, Sarah D., primary, Grönberg, Henrik, primary, Wiklund, Fredrik, primary, Xu, Jianfeng, primary, Vatten, Lars J., primary, Hveem, Kristian, primary, Kumle, Merethe, primary, Tucker, Margaret, primary, Hoover, Robert N., primary, Fraumeni, Joseph F., primary, Hunter, David J., primary, Thomas, Gilles, primary, Chatterjee, Nilanjan, primary, Chanock, Stephen J., primary, and Yeager, Meredith, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure S1 from Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer

Author

Pachynski, Russell K., primary, Kim, Eric H., primary, Miheecheva, Natalia, primary, Kotlov, Nikita, primary, Ramachandran, Akshaya, primary, Postovalova, Ekaterina, primary, Galkin, Ilia, primary, Svekolkin, Viktor, primary, Lyu, Yang, primary, Zou, Qiong, primary, Cao, Dengfeng, primary, Gaut, Joseph, primary, Ippolito, Joseph E., primary, Bagaev, Alexander, primary, Bruttan, Maria, primary, Gancharova, Olga, primary, Nomie, Krystle, primary, Tsiper, Maria, primary, Andriole, Gerald L., primary, Ataullakhanov, Ravshan, primary, and Hsieh, James J., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results